<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/37DE1B14-06DD-4E06-AAC5-56F5BBED7FFF"><gtr:id>37DE1B14-06DD-4E06-AAC5-56F5BBED7FFF</gtr:id><gtr:name>MRC Toxicology Unit</gtr:name><gtr:address><gtr:line1>Hodgkin Building</gtr:line1><gtr:line2>University of Leicester</gtr:line2><gtr:line3>PO Box 138,  Lancaster Road</gtr:line3><gtr:line4>Leicester</gtr:line4><gtr:postCode>LE1 9HN</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/37DE1B14-06DD-4E06-AAC5-56F5BBED7FFF"><gtr:id>37DE1B14-06DD-4E06-AAC5-56F5BBED7FFF</gtr:id><gtr:name>MRC Toxicology Unit</gtr:name><gtr:address><gtr:line1>Hodgkin Building</gtr:line1><gtr:line2>University of Leicester</gtr:line2><gtr:line3>PO Box 138,  Lancaster Road</gtr:line3><gtr:line4>Leicester</gtr:line4><gtr:postCode>LE1 9HN</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles/><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U132670601"><gtr:id>7078A9F2-E7B7-4521-8812-F88C6E65A65E</gtr:id><gtr:title>Stress responses, oncogenic lesions and cell fate decisions</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U132670601</gtr:grantReference><gtr:abstractText>In the context of multicellular organisms, cell injury and/or alterations of the cellular response to cell injury can lead to deregulated growth, enhanced survival, cellular transformation and ultimately cancer. Therefore, the relationship between injury and cancer appears as essential, although not fully understood under the mechanistic point of view. In addition, modifications of the cellular response to injury profoundly affect the efficacy of cancer therapy. Our work is focused on how cancer-associated genetic lesions resulting in either oncogene activation or inhibition of tumour suppressors modulate cell growth and cell death and the response to injury. This is crucial to understand how the process of cancerogenesis works and will potentially unveil new targets for cancer therapy.</gtr:abstractText><gtr:technicalSummary>A fundamental task in Toxicology is to understand cell and tissue response to injury. Cells have a repertoire of stereotypic responses to stress that can be triggered by chemicals and be involved in disease pathogenesis. A clear link exists between cell injury and cancer pathogenesis: 1) cellular stress; 2) oncogenic lesions often target tumour suppressive pathways, which act as crucial checkpoints of the cellular response to exogenous and endogenous insults. As a result, cells at the pre-neoplastic stage carrying oncogenic lesions can progress through impaired checkpoints and further accumulate damage, thus leading to full blown transformation. Finally, because of defective checkpoints the toxic effects of anti-cancer drugs are often blunted in cancer cells. The central theme of my Programme has two major objectives: i) to reveal the fundamental events that govern transformation and in particular to dissect the key tumour suppressive pathways involved; ii) to uncover mechanisms underlying resistance to therapy. My work stems out of my previous studies on two subtypes of myeloid leukaemias: acute promyelocytic leukaemia (APL) and chronic myelogenous leukaemia (CML). My work has led to two key discoveries: i) I revealed an unexpected role of the tumour suppressor PML at the level of progenitor/stem cells in the nervous system; ii) I discovered that autophagy inhibition sensitises CML stem cells to therapy. These findings revealed fundamental mechanisms underlying growth control at the level of both normal and cancerous progenitor / stem cells and also have potentially important translational ramifications. My programme has strong collaborative interactions with the intramural programmes of the Toxicology Unit as well as with other leading laboratories, which bring relevant interdisciplinary expertise to this Programme, linking basic and clinical research. The main aims of my Programme are: 1. To elucidate the role of PML and components of its network in the regulation of neurogenesis and in tumours of the nervous system originating from progenitor/stem cells 2. To define the role of autophagy in cancer cells and tumour-initiating cells upon therapy Our approach emphasizes genetics and the use of RNA interference-based technologies, and we take advantage of primary cell culture.</gtr:technicalSummary><gtr:fund><gtr:end>2009-12-01</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2002-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>2125177</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>211000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project grant</gtr:description><gtr:end>2016-08-02</gtr:end><gtr:fundingOrg>Association for International Cancer Research (AICR)</gtr:fundingOrg><gtr:id>0EDB1F33-141F-403B-8989-A56816D5530B</gtr:id><gtr:outcomeId>CH3PF4DGa5p</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>466494</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project grant</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>6708B64B-3C70-486C-BF7B-F71F0446A9D4</gtr:id><gtr:outcomeId>5461fea5738401.00650730</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2000000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>Consolidator grant</gtr:description><gtr:end>2019-05-02</gtr:end><gtr:fundingOrg>European Research Council (ERC)</gtr:fundingOrg><gtr:id>6065CC56-8A44-4B5C-9FDC-4D4C52119AC8</gtr:id><gtr:outcomeId>5461feea212dc5.21098278</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2014-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>350000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Project Grant</gtr:description><gtr:end>2013-01-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>7471E19F-0A52-4F00-921A-FBFF30791752</gtr:id><gtr:outcomeId>54634266b49a19.02031574</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Development of inhibitors of the E3 ligase Itch as regulator of p73 function in cancer I contributed to the work led by Prof Gerry Melino at the MRC Toxicology Unit</gtr:description><gtr:grantRef>MC_U132670601</gtr:grantRef><gtr:id>84013E95-3253-46C0-BC7E-D7FDB1036619</gtr:id><gtr:impact>Licensing income</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>99178BB9192</gtr:outcomeId><gtr:patentId>US2009306187</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Development of inhibitors of the E3 ligase Itch as regulator of p73 function in cancer</gtr:title><gtr:yearProtectionGranted>2009</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>I have found a new combination of anti-cancer drugs that targets the cancer stem cell compartment in primary patient samples.</gtr:description><gtr:id>48A21BE9-A7E6-4541-9D57-5E07CE6D96D9</gtr:id><gtr:impact>My work constitutes the founding ground for a clinical study being submitted as a MRC grant application for the &amp;quot;Disease or System-Based Stem Cell Research Collaborative Programme&amp;quot; October 2008 Call. The main objective of this application would be to conduct a Phase 1 clinical trial to assess tolerability of the abovementioned combination and its effect on minimal residual disease.</gtr:impact><gtr:outcomeId>15CA017BCAC</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>clinical trial</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2009</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Previous work in the laboratory had led to a clinical trial for the use of the autophagy inhibitor hydroxychloroquine in chronic myeloid leukaemia patients. Further work has led to new Phase II trial for the use of the same inhibitor in the context of elderly glioblastoma multiforme patients (recruiting)</gtr:description><gtr:id>A9049FC7-C437-43F3-A175-3A6D8573DCB4</gtr:id><gtr:impact>This new combinatorial treatment constitutes a new modality for treatment of elderly glioblastoma patients. The study is currently recruiting.</gtr:impact><gtr:outcomeId>e4AnnWAYFG5</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>clinical trial</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:url>http://clinicaltrials.gov/ct2/show/NCT01602588?term=hydroxychloroquine+glioma&amp;rank=1</gtr:url><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>We have generated a new genetic line for conditional inactivation of the histone chaperone DAXX</gtr:description><gtr:id>F0B5237E-256A-418E-B027-37049BB29775</gtr:id><gtr:impact>Not yet measurable as research tool has just been generated</gtr:impact><gtr:outcomeId>546202646afd17.54356997</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Genetic line</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>7509807F-9012-4742-B848-D63311761BB4</gtr:id><gtr:title>TAp63 and DeltaNp63 in cancer and epidermal development.</gtr:title><gtr:parentPublicationTitle>Cell cycle (Georgetown, Tex.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cf02bfffc596a84b2aa376016aa486ba"><gtr:id>cf02bfffc596a84b2aa376016aa486ba</gtr:id><gtr:otherNames>Candi E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1551-4005</gtr:issn><gtr:outcomeId>54633d8d92a7f5.58479695</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BA1DB6A1-59B9-4976-A414-EED25D5ADD61</gtr:id><gtr:title>The nystagmus-associated FRMD7 gene regulates neuronal outgrowth and development.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8b6288dbdd76ee1cdeea3e0372ff95b4"><gtr:id>8b6288dbdd76ee1cdeea3e0372ff95b4</gtr:id><gtr:otherNames>Betts-Henderson J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>m5bDhqu9wiL</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>57D78A22-54A8-49F1-8152-3D67C17569A3</gtr:id><gtr:title>Suppression of autophagy by BCR/ABL.</gtr:title><gtr:parentPublicationTitle>Frontiers in bioscience (Scholar edition)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/089dd79ce38bab46e98b3c15728604db"><gtr:id>089dd79ce38bab46e98b3c15728604db</gtr:id><gtr:otherNames>Calabretta B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1945-0516</gtr:issn><gtr:outcomeId>pm_14016_26_22202070</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C702C59F-3BB6-4A15-AFF6-BD222CDABCE6</gtr:id><gtr:title>Lack of TRF2 in ALT cells causes PML-dependent p53 activation and loss of telomeric DNA.</gtr:title><gtr:parentPublicationTitle>The Journal of cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4a10d825a81423a13571a4af0f359eeb"><gtr:id>4a10d825a81423a13571a4af0f359eeb</gtr:id><gtr:otherNames>Stagno D'Alcontres M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0021-9525</gtr:issn><gtr:outcomeId>1DBEF60D509</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>174A04D8-D23D-49B5-A297-A87252111F53</gtr:id><gtr:title>PML involvement in the p73-mediated E1A-induced suppression of EGFR and induction of apoptosis in head and neck cancers.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a6d65294e81ceb791ff78c3899b18522"><gtr:id>a6d65294e81ceb791ff78c3899b18522</gtr:id><gtr:otherNames>Klanrit P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>R5DeEoHeiad</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>79E420D0-E35D-40E2-8EC0-91B61F3FB0BF</gtr:id><gtr:title>Upregulation of nuclear-encoded mitochondrial LON protease in HAART-treated HIV-positive patients with lipodystrophy: implications for the pathogenesis of the disease.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f5880984f3365e7650c5389108543717"><gtr:id>f5880984f3365e7650c5389108543717</gtr:id><gtr:otherNames>Pinti M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>MjdgjzdBTyE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1B2F80EB-A18F-4656-9397-81651457AA8D</gtr:id><gtr:title>The tumor suppressor Pml regulates cell fate in the developing neocortex.</gtr:title><gtr:parentPublicationTitle>Nature neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/afbc237fb3f951461cbdf1937465740e"><gtr:id>afbc237fb3f951461cbdf1937465740e</gtr:id><gtr:otherNames>Regad T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1097-6256</gtr:issn><gtr:outcomeId>WSLgdstxWEu</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B14A23FB-1F1F-48B5-9E94-7DACE0CC5BF4</gtr:id><gtr:title>The role of autophagy in clinical practice.</gtr:title><gtr:parentPublicationTitle>Clinical oncology (Royal College of Radiologists (Great Britain))</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/085ecb45b4a0a7796a32afe4b9279903"><gtr:id>085ecb45b4a0a7796a32afe4b9279903</gtr:id><gtr:otherNames>Swampillai AL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0936-6555</gtr:issn><gtr:outcomeId>pm_14016_26_22032864</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>30657494-1509-4193-84FE-1401B3A9D0C4</gtr:id><gtr:title>Tumor suppressive pathways in the control of neurogenesis.</gtr:title><gtr:parentPublicationTitle>Cellular and molecular life sciences : CMLS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/54515a3c8ed1b31a9355cf483d04656a"><gtr:id>54515a3c8ed1b31a9355cf483d04656a</gtr:id><gtr:otherNames>Bartesaghi S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1420-682X</gtr:issn><gtr:outcomeId>pm_14016_26_22802124</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3819CEAD-14F9-4D5D-A9DA-66A395B09153</gtr:id><gtr:title>New insights into the cytoplasmic function of PML.</gtr:title><gtr:parentPublicationTitle>Histology and histopathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3f4489f0eb793f589f4126722ffe33d2"><gtr:id>3f4489f0eb793f589f4126722ffe33d2</gtr:id><gtr:otherNames>Salomoni P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0213-3911</gtr:issn><gtr:outcomeId>54633d8db9f170.04436661</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3E72A97C-9DFB-4D0F-B066-97B9176AA5DB</gtr:id><gtr:title>Role of the promyelocytic leukaemia protein in cell death regulation.</gtr:title><gtr:parentPublicationTitle>Cell death &amp; disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3f4489f0eb793f589f4126722ffe33d2"><gtr:id>3f4489f0eb793f589f4126722ffe33d2</gtr:id><gtr:otherNames>Salomoni P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>pm_14016_26_22237204</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>69BCD543-D49C-4BC7-9EF8-DE576EFF3035</gtr:id><gtr:title>The PML-nuclear body associated protein Daxx regulates the cellular response to CD40.</gtr:title><gtr:parentPublicationTitle>Cell death and differentiation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3f4489f0eb793f589f4126722ffe33d2"><gtr:id>3f4489f0eb793f589f4126722ffe33d2</gtr:id><gtr:otherNames>Salomoni P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1350-9047</gtr:issn><gtr:outcomeId>54633d8c58cf31.00186868</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8986A2AC-A668-47AE-8F6D-A3E3CE7F5763</gtr:id><gtr:title>Loss of thymidine kinase 2 alters neuronal bioenergetics and leads to neurodegeneration.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/54515a3c8ed1b31a9355cf483d04656a"><gtr:id>54515a3c8ed1b31a9355cf483d04656a</gtr:id><gtr:otherNames>Bartesaghi S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>NirTSJxMyEX</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>30191AEE-8141-4B71-ADAA-53F7805F3C7F</gtr:id><gtr:title>Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a1448bee0ae56bd58fecff6db43339f5"><gtr:id>a1448bee0ae56bd58fecff6db43339f5</gtr:id><gtr:otherNames>Bellodi C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn><gtr:outcomeId>sTVn5SN13TV</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>99E4937B-7671-401C-BD6A-328C689FF35F</gtr:id><gtr:title>The E3 ubiquitin ligase Itch controls the protein stability of p63.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c5ee5a13f7d6b0787d4919dd19ba893a"><gtr:id>c5ee5a13f7d6b0787d4919dd19ba893a</gtr:id><gtr:otherNames>Rossi M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>54633d8d0efc85.25156070</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>25920F96-55C8-4172-8798-974A0430A557</gtr:id><gtr:title>The PML-Interacting Protein DAXX: Histone Loading Gets into the Picture.</gtr:title><gtr:parentPublicationTitle>Frontiers in oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3f4489f0eb793f589f4126722ffe33d2"><gtr:id>3f4489f0eb793f589f4126722ffe33d2</gtr:id><gtr:otherNames>Salomoni P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2234-943X</gtr:issn><gtr:outcomeId>pm_14016_26_23760585</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C5092A6C-6877-48DE-BAE9-CAC3BC68DC8A</gtr:id><gtr:title>Daxx: death or survival protein?</gtr:title><gtr:parentPublicationTitle>Trends in cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3f4489f0eb793f589f4126722ffe33d2"><gtr:id>3f4489f0eb793f589f4126722ffe33d2</gtr:id><gtr:otherNames>Salomoni P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0962-8924</gtr:issn><gtr:outcomeId>54633d8c8240a9.19809237</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8BE639BE-1C7F-41E6-AD5F-23CAE432BF2A</gtr:id><gtr:title>Autophagy in chronic myeloid leukaemia: stem cell survival and implication in therapy.</gtr:title><gtr:parentPublicationTitle>Current cancer drug targets</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/35a04edb6a7bdaaaa93878eafd349f8c"><gtr:id>35a04edb6a7bdaaaa93878eafd349f8c</gtr:id><gtr:otherNames>Helgason GV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1568-0096</gtr:issn><gtr:outcomeId>pm_14016_26_23941517</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DDCA5DC2-7EBE-4328-ABB9-C7EDC5C93115</gtr:id><gtr:title>HIV: no PUMA no death?</gtr:title><gtr:parentPublicationTitle>Cell death and differentiation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3f4489f0eb793f589f4126722ffe33d2"><gtr:id>3f4489f0eb793f589f4126722ffe33d2</gtr:id><gtr:otherNames>Salomoni P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2004-01-01</gtr:date><gtr:issn>1350-9047</gtr:issn><gtr:outcomeId>54633d8add0480.45913043</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E2D9F4A6-564C-4B3D-9D65-80B525ECEDEE</gtr:id><gtr:title>MOZ-TIF2 inhibits transcription by nuclear receptors and p53 by impairment of CBP function.</gtr:title><gtr:parentPublicationTitle>Molecular and cellular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d33541c985397c3a1942123da637ea07"><gtr:id>d33541c985397c3a1942123da637ea07</gtr:id><gtr:otherNames>Kindle KB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0270-7306</gtr:issn><gtr:outcomeId>54633d8b697d91.91362844</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7759E4C3-9B82-4549-96D1-78B7F0B027B1</gtr:id><gtr:title>Inhibition of autophagy: a new strategy to enhance sensitivity of chronic myeloid leukemia stem cells to tyrosine kinase inhibitors.</gtr:title><gtr:parentPublicationTitle>Leukemia &amp; lymphoma</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/089dd79ce38bab46e98b3c15728604db"><gtr:id>089dd79ce38bab46e98b3c15728604db</gtr:id><gtr:otherNames>Calabretta B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1026-8022</gtr:issn><gtr:outcomeId>pm_14016_26_21250825</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5869118E-3989-401E-8756-9831378B7B34</gtr:id><gtr:title>Targeted therapies and autophagy: new insights from chronic myeloid leukemia.</gtr:title><gtr:parentPublicationTitle>Autophagy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3f4489f0eb793f589f4126722ffe33d2"><gtr:id>3f4489f0eb793f589f4126722ffe33d2</gtr:id><gtr:otherNames>Salomoni P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1554-8627</gtr:issn><gtr:outcomeId>FHRWTwa1B8y</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1B03D4C9-2FEC-4A64-8422-9FAF947D3BC4</gtr:id><gtr:title>Changes in mitochondrial RNA production in cells treated with nucleoside analogues.</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8f446e86d6836d8e6a5da49dfe563b87"><gtr:id>8f446e86d6836d8e6a5da49dfe563b87</gtr:id><gtr:otherNames>Galluzzi L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>54633d8bb5a208.17138359</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C30760F7-1998-408A-B158-A50FC2871900</gtr:id><gtr:title>Anti-HIV drugs and the mitochondria.</gtr:title><gtr:parentPublicationTitle>Biochimica et biophysica acta</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f5880984f3365e7650c5389108543717"><gtr:id>f5880984f3365e7650c5389108543717</gtr:id><gtr:otherNames>Pinti M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0006-3002</gtr:issn><gtr:outcomeId>54633d8ccfcb84.49919573</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5DA55AF0-C237-4133-A659-2FAF7046DEDD</gtr:id><gtr:title>Guidelines for the use and interpretation of assays for monitoring autophagy.</gtr:title><gtr:parentPublicationTitle>Autophagy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3338e204a3c58e1fab88cb3342a71645"><gtr:id>3338e204a3c58e1fab88cb3342a71645</gtr:id><gtr:otherNames>Klionsky DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1554-8627</gtr:issn><gtr:outcomeId>pm_14016_26_22966490</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5B7321A9-BEF3-49EA-96BD-583415119B2F</gtr:id><gtr:title>Ubiquitin-dependent degradation of p73 is inhibited by PML.</gtr:title><gtr:parentPublicationTitle>The Journal of experimental medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7876abe36dc197edd850bcd158433472"><gtr:id>7876abe36dc197edd850bcd158433472</gtr:id><gtr:otherNames>Bernassola F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2004-01-01</gtr:date><gtr:issn>0022-1007</gtr:issn><gtr:outcomeId>54633d8b0e5fc8.81564994</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4B7BBF7B-712A-4D81-897D-53B22C410594</gtr:id><gtr:title>Definition of pRB- and p53-dependent and -independent steps in HIRA/ASF1a-mediated formation of senescence-associated heterochromatin foci.</gtr:title><gtr:parentPublicationTitle>Molecular and cellular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6709bfc7d7af0e25cd49004e8493b04d"><gtr:id>6709bfc7d7af0e25cd49004e8493b04d</gtr:id><gtr:otherNames>Ye X</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0270-7306</gtr:issn><gtr:outcomeId>54633d8d5ccbf9.60550336</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D0166AB2-18AA-4D23-B651-7053CC5B0AD4</gtr:id><gtr:title>Daxx is required for stress-induced cell death and JNK activation.</gtr:title><gtr:parentPublicationTitle>Cell death and differentiation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bd59c422ade9dd75d9e0dba8d706baa1"><gtr:id>bd59c422ade9dd75d9e0dba8d706baa1</gtr:id><gtr:otherNames>Khelifi AF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>1350-9047</gtr:issn><gtr:outcomeId>54633d8bdd1058.95404889</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>58760982-39B6-49FA-9C98-0B6C0A64B8CF</gtr:id><gtr:title>Inhibition of oxidative metabolism leads to p53 genetic inactivation and transformation in neural stem cells.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/54515a3c8ed1b31a9355cf483d04656a"><gtr:id>54515a3c8ed1b31a9355cf483d04656a</gtr:id><gtr:otherNames>Bartesaghi S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>564207b3252159.60720350</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9AF820C9-2EE3-4F8F-AD2E-31DD81B3B4FB</gtr:id><gtr:title>A cytoplasmic PML mutant inhibits p53 function.</gtr:title><gtr:parentPublicationTitle>Cell cycle (Georgetown, Tex.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a1448bee0ae56bd58fecff6db43339f5"><gtr:id>a1448bee0ae56bd58fecff6db43339f5</gtr:id><gtr:otherNames>Bellodi C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1551-4005</gtr:issn><gtr:outcomeId>54633d8d384537.97291682</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C833A645-0174-484E-9E62-B7E180BDBC93</gtr:id><gtr:title>Altered mitochondrial RNA production in adipocytes from HIV-infected individuals with lipodystrophy.</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8f446e86d6836d8e6a5da49dfe563b87"><gtr:id>8f446e86d6836d8e6a5da49dfe563b87</gtr:id><gtr:otherNames>Galluzzi L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>54633d8c34dc51.48822712</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>068326A6-E12E-4A7A-A598-08F1B010A959</gtr:id><gtr:title>Regulation of the p73 protein stability and degradation.</gtr:title><gtr:parentPublicationTitle>Biochemical and biophysical research communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/55be65089c51411de3ae51712e7d01e8"><gtr:id>55be65089c51411de3ae51712e7d01e8</gtr:id><gtr:otherNames>Oberst A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0006-291X</gtr:issn><gtr:outcomeId>54633d8c0e78a8.36405598</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A2F0443F-6F54-436E-889F-CD4FE8230E04</gtr:id><gtr:title>The role of PML in the nervous system.</gtr:title><gtr:parentPublicationTitle>Molecular neurobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3f4489f0eb793f589f4126722ffe33d2"><gtr:id>3f4489f0eb793f589f4126722ffe33d2</gtr:id><gtr:otherNames>Salomoni P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0893-7648</gtr:issn><gtr:outcomeId>pm_14016_26_21161613</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3E03066E-6690-4353-91A9-FC00D243C4D8</gtr:id><gtr:title>Cytoplasmic function of mutant promyelocytic leukemia (PML) and PML-retinoic acid receptor-alpha.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a1448bee0ae56bd58fecff6db43339f5"><gtr:id>a1448bee0ae56bd58fecff6db43339f5</gtr:id><gtr:otherNames>Bellodi C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>54633d8ca7e376.69163422</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9FC990D5-B9CF-4918-BB72-42B1091631EF</gtr:id><gtr:title>PML depletion disrupts normal mammary gland development and skews the composition of the mammary luminal cell progenitor pool.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ce73e661495882f5061c864c6e2c1985"><gtr:id>ce73e661495882f5061c864c6e2c1985</gtr:id><gtr:otherNames>Li W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>bq7mBahM3bE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>23608160-66C1-44A4-8591-111B494CC7D7</gtr:id><gtr:title>Calcium-dependent dephosphorylation of the histone chaperone DAXX regulates H3.3 loading and transcription upon neuronal activation.</gtr:title><gtr:parentPublicationTitle>Neuron</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4fc7a7d15550289f283194744b5fa9d2"><gtr:id>4fc7a7d15550289f283194744b5fa9d2</gtr:id><gtr:otherNames>Michod D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0896-6273</gtr:issn><gtr:outcomeId>pm_14016_26_22500635</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6EABD969-480E-4CE3-B2C7-986423E6A206</gtr:id><gtr:title>Quercetin inhibits lymphocyte activation and proliferation without inducing apoptosis in peripheral mononuclear cells.</gtr:title><gtr:parentPublicationTitle>Leukemia research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/73c0c322829e8cdd61b121a10e3a5ef8"><gtr:id>73c0c322829e8cdd61b121a10e3a5ef8</gtr:id><gtr:otherNames>Lugli E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0145-2126</gtr:issn><gtr:outcomeId>F69EA044920</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>71CAA399-D45F-4110-A95A-1AE4402B1AA3</gtr:id><gtr:title>New insights into the role of PML in tumour suppression.</gtr:title><gtr:parentPublicationTitle>Cell research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3f4489f0eb793f589f4126722ffe33d2"><gtr:id>3f4489f0eb793f589f4126722ffe33d2</gtr:id><gtr:otherNames>Salomoni P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1001-0602</gtr:issn><gtr:outcomeId>54633d8e5f8852.01769263</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4221C020-5621-47E6-8697-EF3374FD3276</gtr:id><gtr:title>Delta N-p73: the enemy within.</gtr:title><gtr:parentPublicationTitle>Cell death and differentiation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3f4489f0eb793f589f4126722ffe33d2"><gtr:id>3f4489f0eb793f589f4126722ffe33d2</gtr:id><gtr:otherNames>Salomoni P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>1350-9047</gtr:issn><gtr:outcomeId>54633d8e170766.51951901</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9980E15E-37A6-44C4-8B51-5BC7E2EFA84A</gtr:id><gtr:title>The Nedd4-binding partner 1 (N4BP1) protein is an inhibitor of the E3 ligase Itch.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/55be65089c51411de3ae51712e7d01e8"><gtr:id>55be65089c51411de3ae51712e7d01e8</gtr:id><gtr:otherNames>Oberst A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>54633d8de0ad07.85985707</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U132670601</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>34</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>CDB856E6-DF2D-4D96-88BD-1CC96FE277EF</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>2.2  Factors relating to physical environment</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>